渤健Biogen (BIIB) 2021年年度报告「NASDAQ」.pdf

1、ANNUAL REPORT2021Neuroscience,Biogen s principal area of focus,is an attractive field with great potential for innovation and scientific breakthroughs that address significant unmet needs of patients living with devastating diseases.”Michel Vounatsos,Chief Executive OfficerCEO LETTERMy fellow stockh

2、olders,The year 2021 was an eventful one for Biogen and our portfolio,and one of continued execution across our base business.Neuroscience,Biogens principal area of focus,is an attractive field with great potential for innovation and scientific breakthroughs that address significant unmet needs of p

3、atients living with devastating diseases.Our emphasis on scientific advancements in service of humanity has driven our leadership in multiple sclerosis(MS),our innovation in spinal muscular atrophy(SMA),and our success in biosimilars.We also achieved important milestones,including:FDA approval of AD

4、UHELM(aducanumab-avwa),the first novel therapy approved for Alzheimers disease since 2003.Important data readouts for potential treatments in depression,stroke,amyotrophic lateral sclerosis(ALS).The formation of Biogen Digital Health,a global unit dedicated to pioneering personalized and digital med

5、icine in neuroscience.To fully realize the significant opportunity we see ahead,we are pursuing a strategic plan that leverages our core competencies in neurology and in related growth areas.Alzheimer s Disease UpdateIn June 2021,the FDA granted accelerated approval to ADUHELM,the first treatment di

6、rected at an underlying pathophysiology of Alzheimers disease,the presence of amyloid beta plaques in the brain.ADUHELMs introduction to the market proceeded more slowly than we would have hoped amid questions around the products mechanism of action and clinical data.In April 2022,we were disappoint